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a b s t r a c t
Objective: The prevalence of diabetes in sub-Saharan Africa is rising, but its relationship to depression is
not well-characterized. This report describes depressive symptom prevalence and associations with
adherence and outcomes among patients with diabetes in a rural, resource-constrained setting.
Methods: In the Webuye, Kenya diabetes clinic, we conducted a chart review, analyzing data including
medication adherence, hemoglobin A1c (HbA1c), clinic attendance, and PHQ-2 depression screening
results.
Results: Among 253 patients, 20.9% screened positive for depression. Prevalence in females was higher
than in males; 27% vs 15% (p ¼ 0.023). Glycemic control trends were better in those screening negative;
at 24 months post-enrollment mean HbA1c was 7.5 for those screening negative and 9.5 for those
screening positive (p ¼ 0.0025). There was a nonsignificant (p ¼ 0.269) trend toward loss to follow-up
among those screening positive.
Conclusions: These findings suggest that depression is common among people with diabetes in rural
western Kenya, which may profoundly impact diabetes control and treatment adherence.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Depression and diabetes mellitus are two chronic disease states
that have a profoundly negative impact on quality of life and overall
life expectancy [1]. They frequently co-occur, and relationships
between both conditions are bidirectional [2]. Some data suggest
that the burden and emotional impact of managing a chronic dis-
ease like diabetes may lead to development of mental health
problems such as depression [3]. Conversely, people with depres-
sion may develop behavioral factors that lead to an overall lack of
self-care, thereby increasing the risk of developing diabetes [4].
There is more than a threefold increase in the prevalence of
depression in people with type 1 diabetes, and nearly a two fold
increase in people with type 2 diabetes. However, there is very
limited data on the prevalence of comorbid depression and diabetes
in sub-Saharan Africa [5].
Both hypotheses present serious implications in the manage-
ment of these comorbid disease states. If diabetes is caused or
exacerbated by depression, then proper management of diabetes
cannot exist without addressing depressive symptoms. Patients
with diabetes experiencing significant depressive symptoms are
less likely to engage in diet and exercise recommendations than are
those without depressive symptoms, and have lower medication
adherence than non-depressed counterparts [6]. Comorbid
depression profoundly impacts diabetes self-management and
treatment adherence, and is associated with significant risk of
complications including stroke and myocardial infarction. Overall,
comorbid depression in individuals with diabetes is associatedwith
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a 1.5-fold increase inmortality risk as compared with thosewithout
depression [7].
As such, co-management of diabetes and depression is critical;
in high income countries programs have been established to
co-manage depression and diabetes, but such programs are
virtually nonexistent in sub-Saharan Africa (SSA) [8]. Globally,
mental illnesses such as depression have become an increasingly
prevalent component of the overall burden of disease [9].
Depression is the second leading cause of disability in young to
middle aged adults in low andmiddle income countries, surpassed
only by HIV/AIDS [10]. Despite this high burden and increasing
global health care strain, limited infrastructure exists to confront
these issues. In Kenya, approximately 0.1% of the national health
care budget is directed toward mental health care [11]. Generally,
there is underdiagnosis of psychiatric illnesses among patients
attending medical facilities in Kenya. This calls for increased
awareness among health care workers, as well as the use of
screening tools that are quick and easy to use in busy clinical
settings [12]. This study seeks to identify the comorbidity of
depression in a rural population of patients receiving care within a
public sector hospital. The Webuye diabetes clinic is located in
Bungoma County, western Kenya. Webuye includes both rural and
semi-urban areas, with a population of around 230,252 people. It
is approximately 380 km west of the capital city, Nairobi. The
diabetes clinic is affiliated with Academic Model Providing Access
to Healthcare (AMPATH), and serves over 650 patients [13].
AMPATH, a partnership between Indiana University School of
Medicine, Moi University School of Medicine, and Moi Teaching
and Referral Hospital in Eldoret, Kenya, has developed one of
Africa’s largest and most effective HIV/AIDS prevention and
treatment programs [14]. AMPATH has since expanded into one of
the first comprehensive chronic disease management programs
in SSA.
This study was approved by the Kenyan based Moi University
Institutional Research and Ethics Committee and the Institutional
Review Board of the North American investigators.
Methods
This study describes prevalence of depressive symptoms as
measured by questions from the ultrabrief depression screening
tool, the Patient Health Questionnaire 2 (PHQ-2) [15], and describes
associations between depressive symptoms and adherence to
medications and clinic visits in a cohort of patients with diabetes in
a rural, resource-constrained clinic setting in western Kenya. In this
retrospective chart review, baseline demographic information was
collected including age, age at diabetes diagnosis, gender, substance
use, food security, travel time to the clinic, income, presence of
comorbid diseases including HIV, tuberculosis, or hypertension, and
family history of diabetes or cardiovascular disease. Responses to
two questions from the PHQ-2, “During the last month have you
been feeling down, depressed or hopeless?” and “During the last
month have you often been bothered by having little interest or
pleasure in doing things?”were recorded. Patients were considered
to screen positive for depression if they answered ‘yes’ to either
question. Longitudinal diabetes management data were also
collected, including current diabetes medication regimen and most
recent HbA1c.
Wilcoxon rank-sum and ManneWhitney tests were used for
statistical analysis of non-parametric data, and Fisher’s exact test
was used for dichotomous data. A p-value of <0.05 was accepted as
statistically significant. These tests were used to identify clinical
and demographic differences between patients with and without a
positive screen for depressive symptoms.
Results
Data from 253 patients were collected, of which 55% were fe-
male. Mean age was 57.6 years (depression screen-positive 58.1
years, depression screen-negative 55.8 years, p ¼ 0.303) with a
mean age of 50.9 at diabetes diagnosis (depression screen-positive
50.9 years, depression screen-negative 47.9 years; p ¼ 0.160).
Overall, 20.9% screened positive for depression (Table 1), with a
statistically significant difference between the proportion ofwomen
(27%) and men (15%) screening positive (p ¼ 0.023). There were no
significant differences between those with and without depressive
symptoms with respect to HIV status, presence of tuberculosis, co-
morbid hypertension, family history of cardiovascular disease or
diabetes, alcohol use, or current diabetes medications.
Regarding diabetes management,13.2% of patients who screened
positive for depressionwere lost to follow-up at 12months following
initial survey, as compared with 7.5% of patients who screened
negative and8.7%ofall diabetes clinicpatients (p¼0.269). Significant
differences inHbA1cbetween the twogroupswerenotdetecteduntil
24 months following initial survey; however, there was a consistent
trend toward higher Hba1cs amongst patients screening positive for
depression as demonstrated in Fig. 1. Baseline HbA1c for depression
screen-negative patients was 9.9 compared to 10.2 for those
screening positive. After 24 months, patients who obtained regular
HbA1cs demonstrated a significant difference, as patients without
depressive symptoms at baseline (N ¼ 29) averaged an HbA1c of 7.5
and those who screened positive (N ¼ 9) averaged 9.5 (p < 0.05).
Table 1
Factors associated with positive depression screen among patients with diabetes
Variable (n) Depression screen positive n (%) p
Gender 0.023*
Male (113) 17 (15.0)
Female (140) 38 (27.1)
TB history 0.623
Positive (6) 1 (16.7)
Negative (243) 52 (21.4)
Aware of HIV status 0.565
Yes (89) 19 (21.4)
No (159) 34 (21.4)
If aware, positive HIV result 0.654
Yes (4) 1 (25.0)
No (79) 18 (22.8)
Hypertension 0.422
Yes (84) 17 (20.2)
No (157) 35 (22.3)
Smoking history 0.183
Yes (7) 0 (0.0)
No (242) 53 (21.9)
Chew tobacco, miraa, or khat 1.000
Yes (3) 0 (0.0)
No (138) 28 (20.3)
Alcohol use 0.311
Yes (26) 4 (15.4)
No (223) 49 (22.0)
Family history of DM 0.445
Yes (84) 17 (20.2)
No (164) 36 (22.0)
Has a caretaker 0.380
Yes (164) 36 (22.0)
No (78) 15 (19.2)
Food insecure 0.058
Yes (83) 23 (27.7)
No (166) 30 (18.1)
Loss to follow up (>12 months) 0.269
Yes (22) 15 (68.2)
No (231) 185 (80.1)
Travel time to clinic (>30 min) 0.601
Yes (48) 32 (66.7)
No (191) 152 (79.6)
*p < 0.05 statistically significant.
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Discussion
These findings suggest that depressive symptoms are common
among patients with diabetes in rural western Kenya. In North
American and European populations, comorbid depression has
consistently been found to impact diabetes adherence, severity,
and outcomes, and depression treatment interventions among
patients with diabetes improve medication adherence and dia-
betes outcomes [16]. A higher proportion of women were screen
positive for depression compared to men and this is thought to be
due in part to a reporting bias as male patients tended to be more
reluctant to report symptoms consistent with depression. The
validity of this finding of a statistically significant difference be-
tween men and women needs to be further evaluated before
conclusive findings are reported on this gender disparity. Though
unable to demonstrate significant differences in diabetes severity
as indicated by most recent HbA1c, our findings suggest that those
with depressive symptoms trend toward a higher mean HbA1c
and more loss to follow up than do those without depressive
symptoms.
This study has several limitations. Firstly, the retrospective na-
ture and small sample size limits the power to detect true associ-
ations with HbA1c or loss to follow up amongst patients with and
without depressive symptoms. Further, the PHQ-2 has not been
widely validated in SSA populations and may therefore not be a
precise indicator of whether individuals screening positive would
meet diagnostic criteria for major depressive disorder. However,
these questions are quick, easy to implement in busy clinic settings,
and positive response to one or both questions indicates distress
that likely impacts individuals’ diabetes disease severity and ability
to engage in treatment.
Further research is needed to investigate prevalence of depres-
sion and relationships between depression, adherence to medica-
tion and clinic visits, and outcomes in this population. Larger
studies of depression among people with diabetes and other
chronic diseases in SSA are indicated to better understand re-
lationships between these comorbid illnesses, as well as the
growing discrepancy between the burden of these conditions and
the infrastructure in place to treat them. As chronic disease man-
agement programs are rolled out in western Kenya and other
resource-constrained settings, it is important to identify and
address depression and other mental illnesses, not only as signifi-
cant sources of distress and disability in their own right, but as
potential barriers to adherence so that treatment interventionsmay
be implemented efficiently and effectively.
Conflict of interest statement
Sonak Pastakia has received fees for serving as a speaker and
consultant for Abbott within the last three years. None of the other
authors have any disclosures to make of conflicts of interest to
report.
Acknowledgments
This research has been supported by the President’s Emergency
Plan for AIDS Relief (PEPFAR) through USAID under the terms of
Cooperative Agreement No. AID-623-A-12-0001. It is made possible
through joint support of the United States Agency for International
Development (USAID). The contents of this research article are the
sole responsibility of AMPATH and do not necessarily reflect the
views of USAID or the United States Government.
Figure 1. HbA1c Trends between depression screen positive and depression screen negative patients with diabetes.
K. Shirey et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 51e54 53
This publication was made possible by the Indiana Clinical and
TranslationalSciences Institute, funded inpartbygrant#UL1TR001108
from the National Institutes of Health, National Center for Advancing
Translational Sciences, Clinical and Translational Sciences Award.
We would like to thank Abbott Fund for providing glucose
testing supplies and funding to support this effort. We would also
like to thank Lilly for their donation of insulin and seed funding to
support our overarching diabetes work.
References
[1] O’Connor PJ, Crain AL, Rush WA, Hanson AM, Fischer LR, Kluznik JC. Does
diabetes double the risk of depression? Ann Fam Med 2009;7:328e35.
[2] Renn BN, Feliciano L, Segal DL. The bidirectional relationship of depression and
diabetes: a systematic review. Clin Psychol Rev 2011;31:1239e46.
[3] Knol MJ, Heerdink ER, Egberts ACG, Geerlings MI, Gorter KJ, Numans ME, et al.
Depressive symptoms in subjects with diagnosed and undiagnosed type 2
diabetes. Psychosom Med 2007;69:300e5.
[4] de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of
depression and diabetes complications: a meta-analysis. Psychosom Med
2001;63:619e30.
[5] Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a
risk factor for the onset of type 2 diabetes mellitus: a metaanalysis. Diabetologia
2006;49:837e45.
[6] Gonzalez JS, Safren SA, Delahanty LM, Cagliero E, Wexler DJ, Meigs JB, et al.
Symptoms of depression prospectively predict poorer self-care in patients
with type 2 diabetes. Diabet Med 2008 Sep;25(9):1102e7.
[7] Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals
with diabetes: a meta-analysis and systematic review. Gen Hosp Psychiatry
2013;35(3):217e25.
[8] Watson LC, Amick HR, Gaynes BN, Brownley KA, Thaker S, Viswanathan M,
et al. Practice-based interventions addressing concomitant depression and
chronic medical conditions in the primary care setting: a systematic re-
view and meta-analysis. J Prim Care Community Health 2013 Oct;4(4):
294e306.
[9] Mathers CD, Loncar D. Projections of global mortality and burden of disease
from 2002 to 2030. PLoS Med 2006;3(11):e442.
[10] Patel V. Mental health in low and middle income countries. Br Med Bull
2007;81-82:81e96.
[11] Kenya National Commission on Human Rights. Silenced minds: the systemic
neglect of the mental health system in Kenya. Nairobi: Kenya; 2011. website,
http://www.knchr.org/Portals/0/Reports/THE_%20MENTAL_HEALTH_REPORT.
pdf [accessed 26.08.12].
[12] Ndetei DM, Khasakhala LI, Kuria MW, Mutiso VN, Ongecha-Owuor FA,
Kokonya DA. The prevalence of mental disorders in adults in different level
general medical facilities in kenya: a cross-sectional study. Ann Gen Psychi-
atry 2009;8:1.
[13] Pastakia SD, Karwa R, Kahn CB, Nyabundi JS. The evolution of diabetes care in
the rural, resource-constrained setting of western Kenya. Ann Pharmacother
2011;45:721e6.
[14] Einterz RM, Kimaiyo S, Mengech HNK, Khwa-Otsyula BO, Esamai F,
Quigley F, et al. Responding to the HIV pandemic: the power of an aca-
demic medical partnership. Acad Med 2007;82:812e8.
[15] Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-
2: validity of a two-item depression screener. Med Care 2003;41:
1284e92.
[16] Markowitz SM, Gonzalez JS, Wilkinson JL, Safren SA. A review of treating
depression in diabetes: emerging findings. Psychosomatics 2011;52:1e18.
K. Shirey et al. / Journal of Clinical & Translational Endocrinology 2 (2015) 51e5454
